Physician profile
Muzaffar Piracha
NPI 1912950320
$8,204.57
in general payments reported to CMS, 2019-2025
50 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $752 · 2021: $1,424 · 2022: $1,239 · 2023: $1,683 · 2024: $1,496 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,425 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,424.88 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,325.46 | 2020-2025 | Freestyle Libre |
| Novo Nordisk INC | $705.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $676.38 | 2019-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $655.12 | 2019-2025 | Korlym |
| Radius Health, INC. | $584.10 | 2020-2025 | |
| Abbvie INC. | $536.75 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $481.63 | 2020-2024 | Strensiq |
| Lilly USA, LLC | $391.16 | 2022-2025 | Jardiance, Mounjaro, Lyumjev |
| Ibsa Pharma INC. | $286.48 | 2020-2023 | Tirosint, Licart |
| Dexcom, INC. | $273.10 | 2022-2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $265.13 | 2021-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $196.24 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Pfizer INC. | $161.35 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $154.94 | 2019-2025 | Keytruda |
| Sanofi-Aventis U.S. LLC | $141.23 | 2019-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muzaffar Piracha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.